NCT04824391View on ClinicalTrials.gov

Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

March 11, 2022

Study Completion Date

March 30, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

ERUCOV-VAC 3 µg/0.5 ml Vaccine

Two IM applications on Days 1 and 28

BIOLOGICAL

ERUCOV-VAC 6 µg/0.5 ml Vaccine

Two IM applications on Days 1 and 28

OTHER

Placebo

Two IM applications on Days 1 and 28

Trial Locations (1)

38039

Erciyes University, Kayseri

All Listed Sponsors
collaborator

TC Erciyes University

OTHER

lead

Health Institutes of Turkey

OTHER_GOV

NCT04824391 - Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 | Biotech Hunter | Biotech Hunter